●公司预计2 0 2 5年年度实现归属于母公司所有者的扣除非经常性损益的净利润- 3 9 , 7 0 0 . 0 0 万元 到- 3 2 , 2 0 0 . 0 0万元，与上年同期相比，亏损将减少2 5 , 5 7 0 . 6 8万元到亏损减少3 3 , 0 7 0 . 6 8万元， 同比亏损减少3 9 . 1 8%到亏损减少5 0 . 6 7%。 一、本期业绩预告情况 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 近期，华大智造发布2 0 2 5年业绩预告。预告称2 0 2 5年亏损同比将减少5 0%以上： 重点内容提示 ●公司经初步测算，深圳华大智造科技股份有限公司（以下简称"公司"）预计2 0 2 5年年度实现 归属于母公司所有者的净利润与上年同期（法定披露数据）相比，实现归属于母公司所有者的 净 利 润- 2 7 , 3 0 0 . 0 0 万 元 到 - 2 2 , 1 0 0 . 0 0万元，与上年同期相比， 亏 损 将 减 少 3 2 , 7 8 2 . 7 0 万 元 到 亏 损减少3 7 , 9 8 2 . 7 0万元 ...

Core Viewpoint - Merck has recently made significant announcements, including the appointment of a new CEO and the acquisition of JSR Life Sciences' chromatography business, aimed at enhancing its biopharmaceutical production capabilities [4]. Group 1: Leadership Changes - Merck officially announced the appointment of Kai Beckmann as the new CEO, effective May 1, 2026 [4]. - Rogier Janssens will take over as the President of Merck China starting February 1, 2026, and will also lead Merck Life Science in China from January 1, 2026, to improve market responsiveness [5][10]. - Current President of Merck China, Marc Horn, will return to Germany for family reasons after contributing significantly to the company's operations and reputation in China over the past two years [6][13]. Group 2: Strategic Acquisitions - Merck announced the acquisition of JSR Life Sciences' chromatography business on October 15, 2023, which is expected to enhance its downstream product offerings and support more efficient biopharmaceutical production [4]. Group 3: Commitment to China - Merck has invested nearly 7 billion RMB in China over the past decade, establishing a strong local presence with approximately 4,500 employees and 21 legal entities [13]. - The company aims to continue deepening its engagement in China, aligning its three main business areas—Life Science, Healthcare, and Electronics—with national strategies to drive sustainable growth and innovation [8][13].

Core Insights - New Zhi Bio is one of the earliest companies in China focused on the research, production, and sales of life science instruments, with over 20 product lines and more than 200 product models covering three main areas: biological sample processing, molecular biology and drug research, and laboratory automation [2] - The company went public on the Beijing Stock Exchange in 2022, marking a significant milestone in its development, and has since expanded its product lines and transformed from a laboratory equipment supplier to a comprehensive service provider covering the entire process from experimentation to mass production [2][6] - New Zhi Bio is leveraging capital to accelerate industry integration, having acquired 55% of Ningbo Afus Constant Temperature Company to enhance its capabilities in industrial temperature control solutions [3] Product Development and Market Strategy - The company has continuously iterated on traditional products while expanding new product lines, including industrial-grade products in ultrasonic processing and customized models for cross-industry applications, maintaining a stable customized business ratio of over 20% [2] - New Zhi Bio emphasizes the importance of strategic flexibility and resource allocation to capture potential opportunities beyond traditional academic research settings [3] - The company is focusing on high-end instruments and global expansion, with plans to establish a localized service network for its foreign trade business, moving from reliance on foreign distributors to a direct service model [5][7] Capital Market and Industry Trends - The Beijing Stock Exchange has played a crucial role in supporting innovative small and medium-sized enterprises, enhancing brand influence and facilitating comprehensive improvements in product development, market expansion, and organizational capabilities for New Zhi Bio [6][9] - The domestic scientific instrument industry is experiencing a historic development window, with significant investments in technology research and talent, allowing some products to approach or exceed international advanced levels [7] - New Zhi Bio aims to become a "research supermarket" and a provider of comprehensive solutions, leveraging the opportunities presented by the Beijing Stock Exchange to collaborate with leading companies in niche markets [9]

Core Insights - The article highlights the growth and strategic direction of New芝生物, emphasizing its transformation into a comprehensive service provider in the life sciences instrument sector since its listing on the Beijing Stock Exchange in 2022 [1][2][6] Company Overview - New芝生物 is one of the early companies in China focusing on the research, production, and sales of life science instruments, currently offering over 200 product models across more than 20 product lines [2] - The company has expanded its product offerings to cover the entire process from experimentation to pilot testing and mass production, moving beyond traditional laboratory equipment [2] Product Development and Innovation - The company continues to iterate on traditional products while expanding new product lines, including industrial-grade applications in ultrasonic processing and customized solutions for various industries [2][3] - New芝生物 has achieved significant technological breakthroughs, allowing it to develop products that meet international standards, such as anaerobic microbial growth curve analyzers [4] Strategic Acquisitions - Following its listing, New芝生物 has accelerated industry consolidation through capital means, exemplified by its acquisition of a 55% stake in 宁波阿弗斯恒温公司 to enhance its industrial temperature control solutions [3] Market Positioning and Global Strategy - The company is shifting its strategic focus towards high-end instruments and global expansion, leveraging the current emphasis on domestic production and technological self-sufficiency [4] - New芝生物 plans to establish a localized service network for its overseas operations, moving from reliance on foreign distributors to a direct service model [5] Capital Market Impact - The establishment of the Beijing Stock Exchange has provided a platform for innovative SMEs like New芝生物 to access capital, enhance brand influence, and attract talent [6] - The company aims to become a "research supermarket" and a provider of comprehensive solutions, benefiting from collaboration opportunities with leading firms in niche markets [6]

Core Viewpoint - Beijing Union Medical College plans to procure various laboratory instruments for its 2025 educational equipment update project, with a total budget exceeding 274 million RMB [2][3]. Summary by Sections Procurement Overview - The total budget for the 2025 educational equipment update project is over 274 million RMB, specifically 274.18 million RMB [3]. - The project includes the procurement of flow cytometers, gas chromatography-mass spectrometry systems, triple quadrupole liquid chromatography-mass spectrometry systems, PCR instruments, ultra-pure water systems, and digital scanning microscopes [3]. Specific Equipment and Budgets - The budget for the procurement of 14 flow cytometers is set at 45.375 million RMB [3]. - The first batch of equipment procurement has a budget of 10.48 million RMB, including various simulators and systems [4]. - The second batch has a budget of 37.95 million RMB, including high-temperature gel chromatography and high-resolution liquid chromatography-mass spectrometry systems [4]. - The third batch has a budget of 9.45 million RMB, including PCR instruments and digital pathology workstations [5]. - The fourth batch has a budget of 13 million RMB, including high-content microscopy workstations and 3D bioprinting systems [6]. Import Regulations - Some equipment categories do not allow bids from foreign companies, indicating a focus on domestic suppliers for certain instruments [3]. Submission Deadlines - Various submission deadlines for bids are set throughout December 2025, with specific dates provided for each batch of equipment [4][5][6].

Core Viewpoint - The resignation of Mr. Li Ning as Vice President of Shenzhen BGI Genomics Co., Ltd. is due to work arrangement reasons, but he will continue to serve as a director of the company and hold positions in its subsidiaries [2][3]. Summary by Sections Resignation Details - Mr. Li Ning's resignation as Vice President is effective immediately upon the board's receipt of his resignation report, and he will maintain his role as a director [2][3]. - His original term as a senior executive was from June 18, 2024, to June 17, 2027 [3]. Shareholding Information - As of the announcement date, Mr. Li holds 122,600 shares directly and has 1,037,880 shares through the company's second employee stock ownership plan [3]. - His associates do not hold any shares in the company [3]. Compliance and Transition - Mr. Li has completed the necessary work handover in accordance with the company's regulations, ensuring that his resignation will not affect the company's daily operations and management [4]. - The board expressed gratitude for Mr. Li's contributions during his tenure [4].

Core Insights - New Zhi Bio, the first stock in life science instruments listed on the Beijing Stock Exchange, emphasizes the importance of innovation and capital support for small and medium-sized enterprises [2][3] Company Overview - New Zhi Bio is one of the earliest companies in China focused on the research, production, and sales of life science instruments, with over 20 product lines and more than 200 product models [3] - The company has transitioned from a laboratory equipment supplier to a comprehensive service provider covering the entire process from experimentation to mass production [3][4] Product Development - The company continues to innovate in traditional product lines while expanding new product lines, including customized models for various industries, maintaining a stable customized business ratio of over 20% [3][4] - New Zhi Bio has achieved significant technological breakthroughs in ultrasonic processing and freeze-drying, enabling the development of industrial-grade products [3] Strategic Expansion - The company is focusing on integrating capital to accelerate industrial consolidation, exemplified by the acquisition of a 55% stake in Ningbo Afus Constant Temperature Company to enhance its industrial temperature control solutions [4] - New Zhi Bio is shifting its strategic focus towards high-end instruments and global expansion, leveraging the increasing emphasis on independent control of scientific instruments at the national level [5][6] Market Positioning - The company has reached a critical stage in achieving independent control over life science instruments, with some products nearing or surpassing international advanced levels [6] - New Zhi Bio plans to establish a localized service network for its overseas markets, moving from reliance on foreign distributors to a direct service model [6] Capital Market Insights - The Beijing Stock Exchange has played a crucial role in supporting innovative small and medium-sized enterprises, fostering a development pattern that balances quantity and quality [7] - The listing has enhanced the company's brand influence, talent attraction, and shareholder structure, allowing it to compete effectively in the talent market [7] - New Zhi Bio aims to become a "research supermarket" and a provider of comprehensive solutions, leveraging opportunities for collaboration with leading companies in niche markets [7]

Core Insights - New Zhi Bio, the first stock in life science instruments listed on the Beijing Stock Exchange, emphasizes the importance of innovation and capital support for small and medium-sized enterprises [1][4] Company Overview - New Zhi Bio has over 20 product lines and more than 200 product models, covering three main areas: biological sample processing, molecular biology and drug research, and laboratory automation [1] - The company has transitioned from a laboratory equipment supplier to a comprehensive service provider covering the entire process from experimentation to mass production [1][2] Product Development - The company has made technological breakthroughs in traditional ultrasonic fields, developing products suitable for industrial applications and expanding its product range in freeze-drying and temperature control equipment [2] - Customization accounts for over 20% of the business, with specialized models developed for various industries, including coal mining and pet food freeze-drying [2] Strategic Direction - New Zhi Bio is focusing on self-controlled high-end instruments and global expansion, with a strategy to build a localized service network for overseas markets [3] - The company aims to create a "research supermarket" and overall solution provider, leveraging the opportunities provided by the Beijing Stock Exchange to collaborate with leading enterprises in niche markets [5] Market Context - The domestic scientific instrument industry is experiencing significant growth, with local companies catching up to international standards in technology and application support [3] - The establishment of the Beijing Stock Exchange is seen as a timely response to the industry's development needs, providing a platform for direct financing and supporting high-quality growth for leading enterprises [4]

Core Viewpoint - New Zhi Bio, the first stock in life science instruments listed on the Beijing Stock Exchange, emphasizes the importance of innovation and capital support for small and medium-sized enterprises, enhancing brand influence and overall capabilities in product development and market expansion [1][6]. Company Overview - New Zhi Bio is one of the earliest companies in China focused on the research, production, and sales of life science instruments, with over 20 product lines and more than 200 product models covering three main areas: biological sample processing, molecular biology and drug research, and laboratory automation [2]. - The company has transitioned from a laboratory equipment supplier to a comprehensive service provider covering the entire process from experimentation to mass production [2]. Product Development and Market Strategy - The company continues to iterate on traditional products while expanding new product lines, with a focus on customer feedback to drive product matrix enrichment [2]. - New Zhi Bio has developed specialized models for cross-industry applications, maintaining a customized business ratio of over 20% [2]. Strategic Direction and Acquisitions - The company is leveraging capital to accelerate industry integration, exemplified by the acquisition of 55% of Ningbo Afus Constant Temperature Company to enhance its industrial temperature control solutions [3]. - The acquisition aligns with New Zhi Bio's existing channels and brand advantages, providing new growth opportunities [3]. Global Expansion and Localization - New Zhi Bio is shifting its strategic focus towards high-end instruments and global layout, with an emphasis on self-sufficiency in scientific instruments [4]. - The company plans to establish a localized service network abroad, moving from reliance on foreign distributors to a "sales-application-after-sales" service model [5]. Capital Market Insights - The Beijing Stock Exchange has played a crucial role in supporting innovative SMEs, fostering a development pattern that balances quantity and quality [6]. - The listing has not only provided financial support but also enhanced talent attraction, optimized shareholder structure, and increased brand influence [6]. - New Zhi Bio aims to become a "research supermarket" and a provider of comprehensive solutions, leveraging opportunities for collaboration with leading companies in niche markets [6].

Core Insights - The article emphasizes the importance of independent innovation and self-reliance in high-end scientific instruments, particularly in the context of China's "14th Five-Year Plan" which promotes technological self-sufficiency and the cultivation of emerging industries [1][3][11] - Haier Biomedical has achieved a significant breakthrough by launching a super-speed centrifuge that exceeds 100,000 RPM, marking a transition from reliance on imports to self-sufficiency in high-end life science instruments [1][5][9] Industry Overview - The demand for ultra-speed centrifuges is increasing due to advancements in cell therapy, vaccine development, and pharmaceutical processes, necessitating higher efficiency and precision in laboratory operations [3][5] - Despite improvements in domestic high-speed centrifuges, the high-end market remains dominated by international brands, with domestic products holding only 38% of the market share as of 2025 [3][5] Company Developments - Haier Biomedical's new centrifuge not only meets international standards in terms of stability and data security but also offers customizable data management features, enhancing safety and compliance for laboratory personnel [5][6] - The company is transitioning from being a mere equipment supplier to a service provider, focusing on creating intelligent laboratory solutions that cater to the specific needs of researchers [6][10] Product Innovations - In addition to the super-speed centrifuge, Haier Biomedical showcased several advanced products at the China International Import Expo, including a rapid freezing instrument and an automated cell expansion system, which are designed to meet the growing demands of life science research [7][8] - The rapid freezing instrument can achieve cooling rates of 10,000°C/s, preserving sample integrity for high-resolution structural analysis [7] Market Potential - The global life science tools market is projected to grow from approximately $161.57 billion in 2023 to over $330.69 billion by 2030, with a compound annual growth rate of 10.8% [11] - As the global pharmaceutical R&D spending increases, the demand for high-quality laboratory instruments and tools is expected to rise significantly, presenting opportunities for companies like Haier Biomedical to expand their market presence [10][11]